tbuckley/cabot-search huggingface dataset:
Christmas Disease
Authors: J. B. Graham, K. M. Brinkhous
Journal: BMJ (1953)

Electro-convulsive Therapy SIR,-The following method is used for giving electroconvulsive therapy at Cork Mental Hospital.The patient receives 1/100 gr.(0.65 mg.) atropine sulphate ten minutes before stimulus, followed by thiopentone sodium,O0.15-0.25 g. intravenously.The syringe is disconnected, but the needle remains intact, and through it is injected succinylcholine, 50 mg.As soon as fibrillation ceases the patient's lungs are inflated 3-4 times with oxygen, using a mask and rebreathing bag.The headpiece is then applied and the electrical stimulus is given.We would like to record the following observation which may be of interest.If the pupil contracts-immediately after the stimulus we have noticed that a convulsion very rarely occurs.Owing to the short time factor involved before the succinylcholine wears away, we now feel it safe to give another stimulus straight away, as there seems to be little danger of a delayed convulsion.We have found this sign very useful and wondered if other readers have had any similar experience.-Weare, etc.,
First Aid to the Injured and Management of the Sick.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EFFICIENCY OF THE HEART
Journal: JAMA (1927)

The respiratory metabolism of the body depends on the supply of oxygen in the circulating blood. During its passage through active tissues the blood becomes depleted in respect to oxygen in proportion to the intensity of the metabolism, on the one hand, and the vigor of the circulation, on the other. The latter factor is maintained in large measure by the work of the blood pump, the heart. Accordingly, a recent writer<sup>1</sup>has remarked that the efficiency of the heart is nothing else than the volume of blood that it can pump in relation to the oxygen requirement in the body. Otherwise defined, it is the ratio of the circulation, its volume per minute, to the oxygen requirement. On this basis the index of efficiency is therefore the arteriovenous oxygen difference during rest and various degrees of muscular exertion. This has become a measurable factor in man, the practical
Postprandial Blood Glucose
Authors: American Diabetes Association
Journal: Diabetes Care (2001)

Individuals with diabetes are at increased risk of developing microvascular complications (retinopathy, nephropathy, and neuropathy) and cardiovascular disease (CVD).The Diabetes Control and Complications Trial (DCCT) (1) and U.K. Prospective Diabetes Study (UKPDS) (2) showed that treatment programs resulting in improved glycemic control, as measured by HbA 1c , reduced the microvascular complications of diabetes.The effect of these treatment programs on reducing CVD was less clear.However, some epidemiological studies suggest that there may be a relationship between glycemic levels and CVD.In the management of diabetes, health care providers usually assess glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, as well as by measuring HbA 1c .Therapeutic goals for HbA 1c and preprandial glucose levels have been established based on the results of controlled clinical trials.Unfortunately, the majority of patients with diabetes fail to achieve their glycemic goals.Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control.Postprandial hyperglycemia is also one of the earliest abnormalities of glucose homeostasis associated with type 2 diabetes and is markedly exaggerated in diabetic patients with fasting hyperglycemia.Several therapies targeted toward lowering PPG excursions are now available and have been shown to improve glycemic control as measured by HbA 1c .However, many questions remain unanswered regarding the definition of PPG and, perhaps most importantly, whether postprandial hyperglycemia has a unique role in the pathogenesis of diabetic complications and should be a specific target of therapy.To address these issues and to provide guidance to health care providers, the American Diabetes Association (ADA) convened a consensus development conference on 24 -26 January 2001 in Atlanta, Georgia.A seven-member panel of experts in diabetes, endocrinology, and metabolism heard selected abstracts and presentations from invited speakers.The panel was then asked to develop a consensus position on the following questions:
Coalworkers' pneumoconiosis.
Authors: J. C. Gilson, P. D. Oldham
Journal: BMJ (1970)

approach to osteoporosis is to attempt to maintain a positive calcium balance throughout its management, and sodium fluoride is given to promote this, when indicated, in a minority of patients.The initial dosage of sodium fluoride is 20 mg.t.d.s., or occasionally q.d.s., and treatment is normally continued for 500 days, until 30 g. have been given.During this period and after cessation of treatment progress is monitored biochemically and by balance studies.Further smaller courses of treatment are given, as indicated.We have looked carefully for signs of toxicity, partic- ularly optic neuritis, and with the above regimen have found none, except for gastric irritation.The latter is eliminated in most patients by taking the drug in capsules and with meals.-Iam, etc.,
Books, Journals, New Media Received
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrective Rhinoplastic Surgery
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transactions of the Section of Laryngology and Otology of the American Medical Association at the Forty-eighth Annual Meeting held in Philadelphia, June 1-4, 1897.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts).
Authors: Michael Lattanzi, Andrew Niederhausern, Junting Zheng, Nadia Bahadur, Chelsea Nichols, Laura Barton, Fenil Gandhi, Kimberly Chan, Alysha Insinga, John Philip, Theodora Bakker, Ashley Marie Regazzi, Brendan John Guercio, Min Yuen Teo, David Henry Aggen, Eugene J. Pietzak, David B. Solit, Irina Ostrovnaya, Neil J. Shah, Gopa Iyer
Journal: Journal of Clinical Oncology (2022)

556 Background: Bladder cancer has one of the highest rates of human epidermal growth factor receptor 2 (HER2) alteration. Novel HER2-directed agents are being investigated in metastatic BC. We sought to define the incidence and clinical characteristics of HER2-altered BC across disease states. Methods: We retrospectively analyzed our single-institution, clinically annotated cohort of urothelial BC pts with available genomic profiling data (MSK-IMPACT). We quantified the prevalence of HER2 alterations, defined as driver mutation (based on OncoKB), and/or amplification, across BC disease states. We examined the association between HER2 alteration and disease progression and survival. The Kaplan-Meier method was used for time-to-event analyses. Results: A total of 1073 BC pts underwent MSK IMPACT profiling of tumor tissue derived from the following disease states: 36% (n = 380) non-muscle invasive (NMI)BC, 41% (n = 443) muscle invasive (MI)BC, and 23% (n = 250) (met)BC. At initial diagnosis, the median age was 67 years, 77% (n = 822) were male, 86% (n = 928) were white, and 66% (n = 710) were smokers. Overall, 16% (n = 177) of pts had any oncogenic HER2 alteration (Table), including 11% with a HER2 driver mutation and 7% with HER2 amplification The most frequent mutations were S310F (40%, n = 53) and S310Y (14%, n = 19). The rate of HER2 amplification was different among the three groups (p = 0.002), 9% in MIBC and metBC compared to 3% in NMIBC. Among 514 pts with NMIBC, the median time to progression (TTP) to MIBC or metBC was 111.6 months (95% Cl: 85.7-NR). Among NMIBC pts, TTP was significantly shorter for HER2-amplified (n = 17) vs. non-amplified (n = 497) (HR = 1.99, 95%CI: 1.05-3.76, p = 0.034, median 26 vs. 114 months). Among pts with metBC receiving frontline platinum-based chemotherapy (n = 143), the median overall survival (OS) was 25.3 months (95%CI: 18.5-33.9). OS was numerically higher in pts with any oncogenic HER2 alteration (n = 26) compared to wild-type (n = 117) (HR = 0.59, 95% Cl: 0.33-1.07, p = 0.082), though this difference was not statistically significant. The median OS for platinum-refractory metBC pts receiving 2 nd line immunotherapy (n = 63) was 10.3 months (95%CI: 7.2-31.6), and the association between OS and HER2 alteration was not significant (HR = 0.57, 95%CI: 0.24-1.37, p = 0.2). Conclusions: HER2 amplification is more frequent in MIBC and metBC than in NMIBC. In NMIBC, HER2 amplification is associated with shorter TTP to MIBC or metBC. HER2 alteration in metBC is associated with a non-significant trend towards improved OS in frontline platinum-treated pts, though this analysis is limited by small sample size.[Table: see text]
Annals Graphic Medicine - Broken Speech
Authors: Charlotte A. Wu, Kimberly R. Myers, Zoe S. Schein, Molly Osborne
Journal: Annals of Internal Medicine (2019)

Web Exclusives7 January 2020Annals Graphic Medicine - Broken SpeechFREECharlotte A. Wu, MD, Kimberly R. Myers, MA, PhD, Zoe S. Schein, MA, and Molly Osborne, MD, PhDCharlotte A. Wu, MDSearch for more papers by this author, Kimberly R. Myers, MA, PhDSearch for more papers by this author, Zoe S. Schein, MASearch for more papers by this author, and Molly Osborne, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/G19-0004 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Download figure Download PowerPoint Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: The authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=G19-0004.Author/Illustrator Information: Charlotte A. Wu, MD, is an internal medicine physician and founder of Harness Health Partners, a health care consultancy focused on health system and technology innovation. She is passionate about leveraging visual storytelling and graphic medicine to improve the health of communities through increased engagement and education of patients, families, learners, and interdisciplinary care teams. Kimberly R. Myers, MA, PhD, is Professor of Humanities and Medicine and Distinguished Educator at Penn State College of Medicine, where she founded and hosts the Penn State Hershey Physician Writers Group. Her primary scholarly interests are medical education, pathography, and graphic medicine. Zoe S. Schein, MA, is a freelance illustrator, writer, and educator in Boston. Schein's artistic work emphasizes visual storytelling and narrative, with particular emphasis on comics, integrated graphic essays, pen-and-ink illustration, and printmaking. View more of Schein's work at www.zoeschein.com. Molly Osborne, MD, PhD, is Professor of Medicine at Oregon Health Sciences University and heads the Integrated Ethics Program at the VA Portland Health Care System. She recognizes the importance of graphic medicine as a teaching tool for intensive care unit end-of-life care and palliative care across all professions.This article was published at Annals.org on 24 December 2019. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 January 2020Volume 172, Issue 1Page: W29-W35KeywordsConflicts of interestDisclosureHealth careHealth information technologyIntensive care unitsMedical educationPalliative carePrevention, policy, and public health ePublished: 24 December 2019 Issue Published: 7 January 2020 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting is appropriate?
Authors: Laura Van Coile, Evelien Verhaeghe, Katia Ongenae, Lieve Brochez, Isabelle Hoorens
Journal: British Journal of Dermatology (2022)

Journal Article Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting is appropriate? Get access Laura Van Coile, Laura Van Coile Department of Dermatology University Hospital Ghent BelgiumCancer Research Institute Ghent (CRIG) Ghent Belgium https://orcid.org/0000-0002-8072-6041 Search for other works by this author on: Oxford Academic Google Scholar Evelien Verhaeghe, Evelien Verhaeghe Department of Dermatology University Hospital Ghent BelgiumCancer Research Institute Ghent (CRIG) Ghent Belgium Search for other works by this author on: Oxford Academic Google Scholar Katia Ongenae, Katia Ongenae Department of Dermatology University Hospital Ghent Belgium Search for other works by this author on: Oxford Academic Google Scholar Lieve Brochez, Lieve Brochez Department of Dermatology University Hospital Ghent BelgiumCancer Research Institute Ghent (CRIG) Ghent Belgium Search for other works by this author on: Oxford Academic Google Scholar Isabelle Hoorens Isabelle Hoorens Department of Dermatology University Hospital Ghent BelgiumCancer Research Institute Ghent (CRIG) Ghent Belgium Correspondence: Isabelle Hoorens. Email: isabelle.hoorens@uzgent.be https://orcid.org/0000-0002-2513-035X Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 187, Issue 2, 1 August 2022, Pages 244–245, https://doi.org/10.1111/bjd.21056 Published: 01 August 2022
Pulmonary calcinosis.
Authors: D Heath, A J Robertson
Journal: Thorax (1977)

The clinical and pathological features are described of a case of pulmonary calcinosis complicating cystic disease of the renal medulla. A histopathological study of the lung revealed calcification in the alveolar walls and in the blood vessels, predominantly in the pulmonary veins and venules. The calcified deposits were also studied by electron microscopy, and appearances suggestive of active growth of the deposits were recognised. Chemical analysis of the lung revealed a calcium content some 55 times greater than that of a normal lung. There was a five-fold increase in magnesium content. Reference is made to the literature demonstrating that the chemical composition of metastic calcification differs according to whether it is visceral or non-visceral in type.
<i>Psychological Medicine. A Manual of Mental Diseases for Practitioners and Students</i>. By Maurice Craig, M. A., M. D. (Cantab.), F. R. C. P. (Lond.). Physicianfor and Lecturer on Psychological Medicine, Guy's Hospital, etc. Third Edition. (<i>Philadelphia: P. Blakiston's Son &amp; Co., 1917</i>.)
Journal: American Journal of Psychiatry (1918)
Rare intrascrotal tumors in a tertiary cancer center: A retrospective case series.
Authors: Mateus Trinconi Cunha, Camila Cardoso, Guilherme Fialho de Freitas, Jamile Almeida Silva, David Queiroz Borges Muniz, Diogo Assed Bastos, Leonardo Cardili, Jose Mauricio Mota
Journal: Journal of Clinical Oncology (2022)

415 Background: Given their rarity, the literature on non-germ cell testicular tumors and paratesticular malignancies is still scarce. The objective of this study is to describe clinical and pathological features, as well as treatment patterns and outcomes, of patients with non-germ cell intrascrotal malignancies. Methods: Patients (pts) with benign or malignant non-germ cell intrascrotal tumors who were older than 18 years-old were deemed eligible. Electronic health records (EHR) were reviewed to assess pts clinical features, and disease characteristics and outcomes. Descriptive statistics was used to report data. RECIST 1.1 was used to determine radiological response to treatment. Time-to-event variables were estimated by the Kaplan-Meier method. Results: EHR of 885 pts with a primary diagnosis of ICD-10 C62 treated in a tertiary cancer center from January 2009 to June 2020 were reviewed for eligibility. 29 pts fulfilled eligibility criteria (Sertoli cell tumors, N = 3; Leydig cell tumors, N = 6; granulosa cell tumor, N = 1; testicular tumor of the androgenital syndrome, N = 1; mesotheliomas, N = 3; liposarcomas, N = 3; leiomyosarcomas N = 2; rhabdomyosarcomas, N = 3; spindle cell sarcomas, N = 3; lymphomas, N = 2; carcinoma of the rete testis, N = 1; primary neuroendocrine tumor of the testis, N = 1). The majority of pts (N = 25) had non-metastatic disease at diagnosis, and underwent upfront orchiectomy. The remaining four patients had metastatic disease at diagnosis (lymphoma, N = 1; sarcomas, N = 3), all positive for lymph node (LN) involvement; one with concurrent visceral metastasis. Six other pts posteriorly developed metastatic disease after a median follow-up of 13 months (IQR: 5.8–33.1 months) (Leydig tumor, N = 1; mesothelioma, N = 2; sarcomas, N = 3). The most common metastatic sites were LN (N = 8, 80%), lung (N = 4, 40%), bone (N = 3, 30%), adrenal gland (N = 2, 20%), peritoneum (N = 1, 10%), and skin (N = 1, 10%). Nine pts (90%) received systemic treatment: vincristine, doxorubicin and cyclophosphamide for rhabdomyosarcomas (N = 3), cisplatin plus pemetrexed for mesotheliomas (N = 2), doxorubicin for liposarcomas (N = 2), doxorubicin plus ifosfamide for liposarcoma (N = 1) and doxorubicin, vincristine, cyclophosphamide, and prednisone plus rituximab for lymphoma (N = 1). Of those, 2 pts achieved partial response and 2 had stable disease. Metastasectomy of a single lung metastasis was performed in a patient with metastatic Leydig cell tumor. Median overall survival was 51.2 and 24.5 months for patients with localized and metastatic disease, respectively. Conclusions: Paratesticular and non-germ cell testicular tumors are extremely rare entities with relatively good prognosis if treated at early stages depending on the underlying histology. Most metastatic disease cases were due to paratesticular sarcomas.
Prescribing clindamycin.
Journal: BMJ (1981)

patients in less time.Its use minimises the patient's suffering and time off work, and also results in a considerable saving in dressings and nurses' and doctors' time.Now that the very occasional risk of a patient developing pseudomembranous colitis is well known and because this complication, should it occur, can be effectively treated for a modest expense, I consider it appropriate to continue giving our patients the benefit of this very effective antibiotic.